Literature DB >> 12406444

Interaction of non-alcoholic fatty liver disease with other liver diseases.

Andrew D Clouston1, Elizabeth E Powell.   

Abstract

Obesity-related steatosis is an increasingly common histological finding in liver biopsies and may co-exist with other chronic liver diseases. Although non-alcoholic fatty liver disease (NAFLD) without true steatohepatitis is generally a benign condition, when another liver disease is present, steatosis may exacerbate the liver damage. In this review, we discuss the interaction of obesity-related steatosis with chronic hepatitis C, alcoholic liver disease, disorders of hepatic iron storage and drug-induced liver disease. The role of weight reduction in minimizing liver injury in patients with chronic hepatitis C is discussed. Finally, we discuss the problems associated with orthotopic liver transplantation for patients with NAFLD.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12406444     DOI： 10.1053/bega.2002.0329

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN： 1521-6918            Impact factor:   3.043


  11 in total

1.  Risk factors for alcoholic liver disease in China.

Authors:  Xiao-Lan Lu; Jin-Yan Luo; Ming Tao; Yan Gen; Ping Zhao; Hong-Li Zhao; Xiao-Dong Zhang; Nei Dong
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

Review 2.  Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease.

Authors:  A-J Demetris; John-G Lunz; Susan Specht; Isao Nozaki
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

Review 3.  Steatosis as a co-factor in chronic liver diseases.

Authors:  Marcello Persico; Achille Iolascon
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

4.  Precision-cut liver slices from diet-induced obese rats exposed to ethanol are susceptible to oxidative stress and increased fatty acid synthesis.

Authors:  Michael J Duryee; Monte S Willis; Courtney S Schaffert; Roger D Reidelberger; Anand Dusad; Daniel R Anderson; Lynell W Klassen; Geoffrey M Thiele
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-27       Impact factor: 4.052

Review 5.  Role of liver biopsy in nonalcoholic fatty liver disease.

Authors:  I L Ke Nalbantoglu; Elizabeth M Brunt
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

6.  Pharmacological ceramide reduction alleviates alcohol-induced steatosis and hepatomegaly in adiponectin knockout mice.

Authors:  Jason M Correnti; Egle Juskeviciute; Aditi Swarup; Jan B Hoek
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

7.  Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life.

Authors:  I J Hickman; J R Jonsson; J B Prins; S Ash; D M Purdie; A D Clouston; E E Powell
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

8.  Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities.

Authors:  Marcello Persico; Mario Masarone; Vincenzo La Mura; Eliana Persico; Francesco Moschella; Monica Svelto; Savino Bruno; Roberto Torella
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

9.  Korean Patients Undergoing Deceased Donor Liver Transplantation for Alcoholic Liver Disease Have Non-Inferior Survival Outcomes than for Hepatitis B Virus: a Real-World Experience without Minimum Abstinence before Transplantation.

Authors:  Suk Kyun Hong; Nam Joon Yi; Hyo Sin Kim; Sung Woo Ahn; Kyung Chul Yoon; Hyeyoung Kim; Kwang Woong Lee; Kyung Suk Suh
Journal:  J Korean Med Sci       Date:  2017-06       Impact factor: 2.153

10.  Inhibition of HCV replication by oxysterol-binding protein-related protein 4 (ORP4) through interaction with HCV NS5B and alteration of lipid droplet formation.

Authors:  In-Woo Park; Jean Ndjomou; Yahong Wen; Ziqing Liu; Neale D Ridgway; C Cheng Kao; Johnny J He
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.